Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.
GC−MS
HCC
UPLC−MS
alpha-fetoprotein
cirrhosis
liver tissues
metabolomics
Journal
Journal of proteome research
ISSN: 1535-3907
Titre abrégé: J Proteome Res
Pays: United States
ID NLM: 101128775
Informations de publication
Date de publication:
02 08 2019
02 08 2019
Historique:
pubmed:
13
6
2019
medline:
16
7
2020
entrez:
13
6
2019
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) causes more than half a million annual deaths worldwide. Understanding the mechanisms contributing to HCC development is highly desirable for improved surveillance, diagnosis, and treatment. Liver tissue metabolomics has the potential to reflect the physiological changes behind HCC development. Also, it allows identification of biomarker candidates for future evaluation in biofluids and investigation of racial disparities in HCC. Tumor and nontumor tissues from 40 patients were analyzed by both gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) platforms to increase the metabolome coverage. The levels of the metabolites extracted from solid liver tissue of the HCC area and adjacent non-HCC area were compared. Among the analytes detected by GC-MS and LC-MS with significant alterations, 18 were selected based on biological relevance and confirmed metabolite identification. These metabolites belong to TCA cycle, glycolysis, purines, and lipid metabolism and have been previously reported in liver metabolomic studies where high correlation with HCC progression is implied. We demonstrated that metabolites related to HCC pathogenesis can be identified through liver tissue metabolomic analysis. Additionally, this study has enabled us to identify race-specific metabolites associated with HCC.
Identifiants
pubmed: 31188000
doi: 10.1021/acs.jproteome.9b00185
pmc: PMC6677583
mid: NIHMS1035714
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3067-3076Subventions
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM123766
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA222155
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA185188
Pays : United States
Références
Adv Exp Med Biol. 2017;965:209-234
pubmed: 28132182
Hepatology. 2013 Jul;58(1):229-38
pubmed: 23463346
Oxid Med Cell Longev. 2018 Nov 4;2018:7512159
pubmed: 30524660
Gastroenterology. 2013 May;144(5):1066-1075.e1
pubmed: 23376425
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Hepatology. 2011 Sep 2;54(3):920-30
pubmed: 21674557
BMC Bioinformatics. 2015 Apr 16;16:118
pubmed: 25888443
World J Hepatol. 2018 Mar 27;10(3):371-378
pubmed: 29599900
Front Immunol. 2018 Jul 30;9:1697
pubmed: 30105018
World J Gastroenterol. 2016 Oct 14;22(38):8584-8595
pubmed: 27784971
Liver Int. 2018 Feb;38 Suppl 1:2-6
pubmed: 29427496
Cell. 2008 Sep 19;134(6):933-44
pubmed: 18805087
Cancer Res. 2013 Aug 15;73(16):4992-5002
pubmed: 23824744
Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9
pubmed: 26979502
Cancers (Basel). 2018 Feb 09;10(2):
pubmed: 29425151
Hepatobiliary Surg Nutr. 2016 Feb;5(1):43-52
pubmed: 26904556
Cancer Manag Res. 2018 Apr 11;10:715-734
pubmed: 29692630
Cancer Res. 2016 May 15;76(10):2912-20
pubmed: 26976432
World J Gastroenterol. 2013 Jun 14;19(22):3423-32
pubmed: 23801834
Trends Biochem Sci. 2017 Feb;42(2):141-154
pubmed: 28029518
Cancer Res. 2018 Aug 15;78(16):4471-4481
pubmed: 29967258
Am J Med. 2015 Jan;128(1):90.e1-7
pubmed: 25116425
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Bioanalysis. 2014;6(12):1657-77
pubmed: 25077626
Clin Chim Acta. 2019 Jan;488:68-75
pubmed: 30389456
World J Hepatol. 2015 Jul 28;7(15):1964-70
pubmed: 26244070